Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Current Deferred Revenue (2024)

Perspective Therapeutics' Current Deferred Revenue history spans 1 years, with the latest figure at $1.4 million for Q4 2024.

  • For Q4 2024, Current Deferred Revenue changed N/A year-over-year to $1.4 million; the TTM value through Dec 2024 reached $1.4 million, changed N/A, while the annual FY2024 figure was $1.4 million, N/A changed from the prior year.
  • Current Deferred Revenue for Q4 2024 was $1.4 million at Perspective Therapeutics, roughly flat from $1.4 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $1.4 million in Q1 2024 and bottomed at $1.4 million in Q1 2024.